about
Pharmacogenetics of Anti-Diabetes Drugs.Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment.Is cytochrome modulation the new frontier for decreasing the risk of cataract?No clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.Pioglitazone in the management of diabetes mellitus after transplantation.Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review.
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Pioglitazone: effect on CYP3A4 activity.
@en
Pioglitazone: effect on CYP3A4 activity.
@nl
type
label
Pioglitazone: effect on CYP3A4 activity.
@en
Pioglitazone: effect on CYP3A4 activity.
@nl
prefLabel
Pioglitazone: effect on CYP3A4 activity.
@en
Pioglitazone: effect on CYP3A4 activity.
@nl
P2093
P2860
P1476
Pioglitazone: effect on CYP3A4 activity.
@en
P2093
Anthony Clarke
David J Edwards
Gail D Anderson
Linda A Jaber
Sandra N Nowak
P2860
P304
P356
10.1177/0091270002042012009
P577
2002-12-01T00:00:00Z